Considering mutational meltdown as a potential SARS-CoV-2 treatment strategy.
作者信息
Jensen Jeffrey D, Lynch Michael
机构信息
School of Life Sciences, Arizona State University, Tempe, AZ, USA.
出版信息
Heredity (Edinb). 2020 May;124(5):619-620. doi: 10.1038/s41437-020-0314-z. Epub 2020 Apr 6.
Abstract
摘要
相似文献
1
Considering mutational meltdown as a potential SARS-CoV-2 treatment strategy.将突变灾难视为一种潜在的新冠病毒治疗策略。
Heredity (Edinb). 2020 May;124(5):619-620. doi: 10.1038/s41437-020-0314-z. Epub 2020 Apr 6.
2
Favipiravir, an antiviral for COVID-19?法匹拉韦，一种用于治疗新冠肺炎的抗病毒药物？
J Antimicrob Chemother. 2020 Jul 1;75(7):2013-2014. doi: 10.1093/jac/dkaa171.
3
Rapid incorporation of Favipiravir by the fast and permissive viral RNA polymerase complex results in SARS-CoV-2 lethal mutagenesis.快速且允许的病毒 RNA 聚合酶复合物使法匹拉韦迅速掺入，导致 SARS-CoV-2 致命突变。
Nat Commun. 2020 Sep 17;11(1):4682. doi: 10.1038/s41467-020-18463-z.
4
Oral favipiravir for patients with delayed SARS-CoV-2 viral RNA clearance: a case series.口服法匹拉韦治疗严重急性呼吸综合征冠状病毒2（SARS-CoV-2）病毒RNA清除延迟患者：病例系列
Crit Care. 2020 Sep 25;24(1):578. doi: 10.1186/s13054-020-03288-5.
5
Metabolomics to Predict Antiviral Drug Efficacy in COVID-19.代谢组学预测COVID-19中抗病毒药物疗效
Am J Respir Cell Mol Biol. 2020 Sep;63(3):396-398. doi: 10.1165/rcmb.2020-0206LE.
6
[Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2): Should we target the virus, the cell or the disease?].[严重急性呼吸综合征冠状病毒2（SARS-CoV-2）：我们应该针对病毒、细胞还是疾病？]
Virologie (Montrouge). 2020 Jun 1;24(3):135-141. doi: 10.1684/vir.2020.0843.
7
An adaptive randomised placebo controlled phase II trial of antivirals for COVID-19 infection (VIRCO): A structured summary of a study protocol for a randomised controlled trial.一项针对 COVID-19 感染的抗病毒药物的适应性随机安慰剂对照 II 期试验（VIRCO）：一项随机对照试验研究方案的结构化总结。
Trials. 2020 Oct 13;21(1):847. doi: 10.1186/s13063-020-04766-5.
8
Statin therapy and SAR-COV-2: an available and potential therapy?他汀类药物治疗与新型冠状病毒2：一种可行且有潜力的治疗方法？
Eur Heart J Cardiovasc Pharmacother. 2020 Sep 1;6(5):333-334. doi: 10.1093/ehjcvp/pvaa050.
9
Sofosbuvir for COVID-19 infection: A potential candidate.索磷布韦用于治疗新型冠状病毒肺炎感染：一个潜在的候选药物。
Indian J Pharmacol. 2020 May-Jun;52(3):232-233. doi: 10.4103/ijp.IJP_675_20. Epub 2020 Aug 4.
10
Coronavirus RNA Proofreading: Molecular Basis and Therapeutic Targeting.冠状病毒RNA校对：分子基础与治疗靶点
Mol Cell. 2020 Sep 3;79(5):710-727. doi: 10.1016/j.molcel.2020.07.027. Epub 2020 Aug 4.
引用本文的文献
1
Genetic consequences of effective and suboptimal dosing with mutagenic drugs in a hamster model of SARS-CoV-2 infection.在新冠病毒（SARS-CoV-2）感染的仓鼠模型中，使用致突变药物进行有效和次优剂量给药的遗传后果。
Virus Evol. 2024 Jan 4;10(1):veae001. doi: 10.1093/ve/veae001. eCollection 2024.
2
SARS2Mutant: SARS-CoV-2 amino-acid mutation atlas database.SARS2突变体：严重急性呼吸综合征冠状病毒2氨基酸突变图谱数据库。
NAR Genom Bioinform. 2023 Apr 24;5(2):lqad037. doi: 10.1093/nargab/lqad037. eCollection 2023 Jun.
3
Developing an appropriate evolutionary baseline model for the study of SARS-CoV-2 patient samples.为 SARS-CoV-2 患者样本研究开发适当的进化基准模型。
PLoS Pathog. 2023 Apr 5;19(4):e1011265. doi: 10.1371/journal.ppat.1011265. eCollection 2023 Apr.
4
The extinction time under mutational meltdown driven by high mutation rates.由高突变率驱动的突变崩溃下的灭绝时间。
Ecol Evol. 2022 Jul 6;12(7):e9046. doi: 10.1002/ece3.9046. eCollection 2022 Jul.
5
SARS-CoV-19 Mutations: is a Blessing or a Curse for Human Being?严重急性呼吸综合征冠状病毒2（SARS-CoV-19）变异：对人类而言是福还是祸？
Ethiop J Health Sci. 2022 Mar;32(2):467-468. doi: 10.4314/ejhs.v32i2.28.
6
Mutation rate of SARS-CoV-2 and emergence of mutators during experimental evolution.严重急性呼吸综合征冠状病毒2（SARS-CoV-2）的突变率及实验进化过程中突变体的出现。
Evol Med Public Health. 2022 Mar 29;10(1):142-155. doi: 10.1093/emph/eoac010. eCollection 2022.
7
The impact of frequently neglected model violations on bacterial recombination rate estimation: a case study in Mycobacterium canettii and Mycobacterium tuberculosis.频繁被忽视的模型违反情况对细菌重组率估计的影响：以卡内蒂分枝杆菌和结核分枝杆菌为例的研究
G3 (Bethesda). 2022 May 6;12(5). doi: 10.1093/g3journal/jkac055.
8
Inferring the distribution of fitness effects in patient-sampled and experimental virus populations: two case studies.推断患者样本和实验病毒群体中适应度效应的分布：两个案例研究。
Heredity (Edinb). 2022 Feb;128(2):79-87. doi: 10.1038/s41437-021-00493-y. Epub 2022 Jan 5.
9
US201 Study: A Phase 2, Randomized Proof-of-Concept Trial of Favipiravir for the Treatment of COVID-19.US201研究：法匹拉韦治疗COVID-19的2期随机概念验证试验。
Open Forum Infect Dis. 2021 Dec 7;8(12):ofab563. doi: 10.1093/ofid/ofab563. eCollection 2021 Dec.
10
Molecular evolutionary characteristics of SARS-CoV-2 emerging in the United States.美国出现的 SARS-CoV-2 的分子进化特征。
J Med Virol. 2022 Jan;94(1):310-317. doi: 10.1002/jmv.27331. Epub 2021 Sep 20.
本文引用的文献
1
Discovering drugs to treat coronavirus disease 2019 (COVID-19).发现治疗2019冠状病毒病（COVID-19）的药物。
Drug Discov Ther. 2020;14(1):58-60. doi: 10.5582/ddt.2020.01012.
2
Therapeutic options for the 2019 novel coronavirus (2019-nCoV).2019新型冠状病毒（2019-nCoV）的治疗选择。
Nat Rev Drug Discov. 2020 Mar;19(3):149-150. doi: 10.1038/d41573-020-00016-0.
3
Two sides of the same coin: A population genetics perspective on lethal mutagenesis and mutational meltdown.同一枚硬币的两面：从群体遗传学角度看致死性诱变和突变崩溃。
Virus Evol. 2017 Mar 2;3(1):vex004. doi: 10.1093/ve/vex004. eCollection 2017 Jan.
4
The Combined Effect of Oseltamivir and Favipiravir on Influenza A Virus Evolution.奥司他韦和法匹拉韦对甲型流感病毒进化的联合作用
Genome Biol Evol. 2017 Jul 1;9(7):1913-1924. doi: 10.1093/gbe/evx138.
5
MUTATION LOAD AND THE SURVIVAL OF SMALL POPULATIONS.突变负荷与小种群的生存
Evolution. 1990 Nov;44(7):1725-1737. doi: 10.1111/j.1558-5646.1990.tb05244.x.
6
Dynamics and Fate of Beneficial Mutations Under Lineage Contamination by Linked Deleterious Mutations.连锁有害突变导致谱系污染下有益突变的动态变化与命运
Genetics. 2017 Mar;205(3):1305-1318. doi: 10.1534/genetics.116.194597. Epub 2017 Jan 18.
7
An experimental evaluation of drug-induced mutational meltdown as an antiviral treatment strategy.作为一种抗病毒治疗策略的药物诱导突变崩溃的实验评估。
Evolution. 2016 Nov;70(11):2470-2484. doi: 10.1111/evo.13041. Epub 2016 Sep 13.
8
Favipiravir (T-705), a novel viral RNA polymerase inhibitor.法匹拉韦（T-705），一种新型的病毒 RNA 聚合酶抑制剂。
Antiviral Res. 2013 Nov;100(2):446-54. doi: 10.1016/j.antiviral.2013.09.015. Epub 2013 Sep 29.
9
Coronaviruses lacking exoribonuclease activity are susceptible to lethal mutagenesis: evidence for proofreading and potential therapeutics.缺乏外切核酸酶活性的冠状病毒易发生致死性突变：校正证据和潜在治疗方法。
PLoS Pathog. 2013 Aug;9(8):e1003565. doi: 10.1371/journal.ppat.1003565. Epub 2013 Aug 15.
10
T-705 (favipiravir) induces lethal mutagenesis in influenza A H1N1 viruses in vitro.T-705（法匹拉韦）在体外诱导甲型 H1N1 流感病毒产生致死性突变。
J Virol. 2013 Apr;87(7):3741-51. doi: 10.1128/JVI.02346-12. Epub 2013 Jan 16.
Zotero 插件